Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASCENDIS PHARMA A/S

(ASND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 2 2975 9247 3756 1216 121-
Enterprise Value (EV)2 2 0195 3266 7485 4435 6465 902
P/E ratio -17,2x-26,5x-16,5x-14,6x-13,1x-16,3x
Yield ------
Capitalization / Revenue 217x443x1 061x806x95,6x27,3x
EV / Revenue 191x398x970x717x88,2x26,3x
EV / EBITDA -13,1x-24,2x-21,0x-12,6x-14,0x-18,5x
Price to Book 8,22x9,97x8,24x8,36x8,58x13,7x
Nbr of stocks (in thousands) 42 03347 74054 00656 81556 815-
Reference price (EUR) 54,6124137108108108
Announcement Date 04/03/201904/01/202003/10/2021---
1 USD in Million
2 EUR in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 10,613,46,957,5964,0224
EBITDA1 -154-220-321-431-402-318
Operating profit (EBIT)1 -155-227-331-453-462-379
Operating Margin -1 463%-1 695%-4 755%-5 962%-722%-169%
Pre-Tax Profit (EBT)1 -130-218-419-405-492-399
Net income1 -130-218-419-403-474-399
Net margin -1 230%-1 630%-6 026%-5 302%-741%-178%
EPS2 -3,17-4,69-8,28-7,36-8,22-6,63
Dividend per Share2 ------
Announcement Date 04/03/201904/01/202003/10/2021---
1 EUR in Million
2 EUR
Previous periodNext period
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 0,751,021,113,688,4312,6
EBITDA1 -121-114-93,1-128--
Operating profit (EBIT)1 -125-118-96,9-119-121-124
Operating Margin -16 709%-11 510%-8 709%-3 242%-1 433%-983%
Pre-Tax Profit (EBT)1 -63,0-134-80,3-123-120-123
Net income1 -62,8-134-80,3-121-120-123
Net margin -8 417%-13 148%-7 219%-3 295%-1 421%-977%
EPS2 -1,17-2,50-1,47-2,28-2,12-2,16
Dividend per Share ------
Announcement Date 05/27/202108/25/202111/10/2021---
1 EUR in Million
2 EUR
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ------
Net Cash position1 278598627677475219
Leverage (Debt / EBITDA) 1,81x2,72x1,95x1,57x1,18x0,69x
Free Cash Flow1 -146-190-291-400-458-350
ROE (Net Profit / Equities) -55,7%-49,7%-58,4%-53,0%-64,5%-53,1%
Shareholders' equity1 234439718760736751
ROA (Net Profit / Asset) -49,1%-43,8%-50,6%-42,1%-60,2%-
Assets1 265498828955788-
Book Value Per Share2 6,6512,416,612,912,67,85
Cash Flow per Share2 -3,48-3,98-5,36-5,51-4,40-5,25
Capex1 2,655,1619,922,021,020,8
Capex / Sales 25,0%38,6%286%289%32,8%9,28%
Announcement Date 04/03/201904/01/202003/10/2021---
1 EUR in Million
2 EUR
Previous periodNext period
Key data
Capitalization (USD) 6 986 004 369
Net sales (EUR) 6 953 000
Net sales (USD) 7 938 240
Number of employees 482
Sales / Employee (EUR) 14 425
Sales / Employee (USD) 16 469
Free-Float 10,5%
Free-Float capitalization (USD) 736 949 793
Avg. Exchange 20 sessions (EUR) 32 071 091
Avg. Exchange 20 sessions (USD) 36 615 565
Average Daily Capital Traded 0,46%
EPS & Dividend